The groundbreaking rise of Viagra has consistently remained a benchmark of pharmaceutical success, however its future within the broader industry now triggers questions about long-term returns . Copycat versions are undercutting market share, causing worries that investing in companies significantly dependent to Viagra's once-dominant position coul